In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
Jakob Roze, CSCS, is a health writer and high-end personal trainer. He is the founder and CEO of RozeFit, a high-end concierge personal training practice and online blog. Floor slides can improve your ...
Low-impact cardio exercises raise your heart rate without stressing your joints. Doing low-impact exercises can lower your risk of heart disease and type 2 diabetes. Common low-impact exercises ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback